X



Oncology

XelodaXeloda

Laboratory: Roche Pharmaceuticals
GROUP THERAPY: Antineoplastic Agents

ACTIVE INGREDIENT: purine analogues: lidocaine + hydrocortisone
THERAPEUTIC ACTION Antineoplastic 
COMPOSITION Each coated tablet contains: 500mg capecitabine
XELODA ® is indicated for the adjuvant treatment after surgery in patients with colon cancer stage III (Dukes' C).

XELODA ® is indicated as monotherapy as first-line mCRC.

XELODA ® in combination with docetaxel is indicated for the treatment of cancer patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy.

Previous therapy should have included an anthracycline.



 

 

 

 

 


Pharmacy Tristaina, your pharmacy in Andorra.
We are at arrangement for any doubt or information that it needs.
Do not doubt to get in touch with us if you want some product specific, or that you do not find in our catalog.

Leave your phone and we will call you